Literature DB >> 24476396

Disseminated peritoneal tuberculosis mimicking advanced ovarian cancer.

I Lataifeh1, I Matalka, W Hayajneh, B Obeidat, H Al Zou'bi, G Abdeen.   

Abstract

The objective was to evaluate the clinical and radiological features of peritoneal tuberculosis (PTB) that resembled advanced ovarian malignancy. A retrospective review of all patients diagnosed with PTB over a period of 10 years was made. The data included: age, presenting symptom(s), CA125 level, microbiological, histological and cytological studies of the surgical specimens. The radiological and operative findings were also reviewed. A total of 16 patients were identified. The median age was 29.5 years (range 13-65 years). The median CA125 level was 319 U/ml (range 45-1,072 U/ml). The most common symptoms were abdominal distention and pain in 13 patients. Imaging studies showed ascites in all patients. Six patients had laparotomy and 10 had laparoscopy procedure. All patients received anti-tuberculosis treatment and had complete cure. A high index of suspicion of PTB is important to avoid unnecessary extended surgery in relatively young patients with nonspecific clinical features.

Entities:  

Mesh:

Year:  2014        PMID: 24476396     DOI: 10.3109/01443615.2013.870140

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  2 in total

1.  The Role of ¹⁸F-FDG PET/CT in the Evaluation of Peritoneal Thickening of Undetermined Origin.

Authors:  Ruohua Chen; Yumei Chen; Liu Liu; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

2.  Proportions of interferon-γ-producing ascites lymphocytes in response to mycobacterial antigens: A help for early diagnosis of peritoneal tuberculosis in a low TB incidence country.

Authors:  Sophie Henrard; Véronique Corbière; Liliane Schandené; Martine Ducarme; Anne Van Praet; Emmanuelle Petit; Mahavir Singh; Camille Locht; Violette Dirix; Françoise Mascart
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.